Ziprasidone: First year experience in a hospital setting

Journal of Psychiatric Practice

Volumn 10, Issue 6, 2004, Pages 361-367

  Centorrino, Franca ^a   Maclean, Elizabeth ^b   Salvatore, Paola ^a   Kidwell, Jennifer E ^a   Fogarty, Kate V ^a   Berry, Judith M ^a   Baldessarini, Ross J ^a  

^a MCLEAN HOSPITAL   (United States)

^b PFIZER INC   (United States)

Author keywords

Mania; Mood disorders; Psychosis; Schizophrenia; Second generation antipsychotic; Ziprasidone

Indexed keywords

ARSENIC TRIOXIDE; CHLORPROMAZINE; DOFETILIDE; DOLASETRON MESILATE; DROPERIDOL; GATIFLOXACIN; HALOFANTRINE; LEVACETYLMETHADOL; MEFLOQUINE; MESORIDAZINE; MESORIDAZINE BESYLATE; MOXIFLOXACIN; NEUROLEPTIC AGENT; PENTAMIDINE; PENTAMIDINE ISETHIONATE; PIMOZIDE; PROBUCOL; PSYCHOTROPIC AGENT; QUINIDINE; QUINIDINE GLUCONATE; QUINIDINE SULFATE; SOTALOL; SPARFLOXACIN; TACROLIMUS; THIORIDAZINE; ZIPRASIDONE;

ADULT; AGITATION; AKATHISIA; ARTICLE; CARDIOTOXICITY; CLINICAL FEATURE; CONFUSION; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MANIA; MEDICAL RECORD; MEMORY DISORDER; PSYCHOSIS; QT INTERVAL; RASH; SCHIZOAFFECTIVE PSYCHOSIS; SCORING SYSTEM; SEDATION; SEIZURE; SIDE EFFECT; SYMPTOMATOLOGY;

ADULT; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER; ELECTROCARDIOGRAPHY; FEMALE; HOSPITALIZATION; HUMANS; INPATIENTS; LENGTH OF STAY; LONG QT SYNDROME; MALE; MIDDLE AGED; MOOD DISORDERS; PIPERAZINES; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; THIAZOLES; TREATMENT OUTCOME;

EID: 10144255847     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200411000-00004     Document Type: Article

References (29)

1. Geodon product information. New York: Pfizer, Inc; July 2002.
2. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial. Neuropsychopharmacology 1999;20:491-505.
3. Stimmel GL, Gutierrez MA, Lee V. Ziprasidone: An atypical antipsychotic drug for the treatment of schizophrenia. Clin Ther 2002;24:21-37.
4. Nasrallah H. Review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003;28(Suppl 1):83-96.
5. Gunasekara NS, Spencer CM, Keating GM. Ziprasidone: A review of its use in schizophrenia and schizoaffective disorder. Drugs 2002;62:1217-51.
6. Glassman AH, Bigger JT. Antipsychotic drugs: Prolonged QTc interval, torsades de pointes, and sudden death. Am J Psychiatry 2001;158:1774-82.
7. Taylor D. Ziprasidone in the management of schizophrenia: The QT interval in context. Ther Practice 2003;17:423-30.
8. Al-Khatib SM, LaPointe NM, Kramer JM, et al. What clinicians should know about the QT interval. JAMA 2003;289:2120-7.
9. Belardinelli L, Antzelevitch C, Vos MA. Assessing predictors of drug-induced torsades de pointes. Trends Pharmacol Sci 2003; 24:619-25.
10. Cubeddu LX. QT prolongation and fatal arrhythmias: Review of clinical implications and effects of drugs. Am J Ther 2003;10:452-7.
11. Beedham C, Miceli JJ, Obach RS. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol 2003;23:229-32.
12. Papakostas GI, Petersen TJ, Nierenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004;65:217-21.
13. Weiden PJ, Iqbal N, Mendelowitz AJ, et al. Best clinical practice with ziprasidone: Update after one year of experience. J Psychiatr Practice 2002;8:81-97.
14. Goff DC, Posever T, Herz L, et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998;18:296-304.
15. Keck PE Jr, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial. Psychopharmacology (Berl) 1998;140:173-84.
16. Keck PE Jr, Reeves KR, Harrigan EP, et al. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: Results from two double- blind, placebo-controlled, multicenter studies. J Clin Psychopharmacol 2001;21:27-35.
17. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
18. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale(BPRS): Recent developments in ascertainment and scaling. Psychopharmacol Bull 1988;24:97-9.
19. Keck PE Jr, Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: A three-week placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003; 160:741-8.
20. Arato M, O'Connor R, Meltzer HY; ZEUS Study Group. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: The Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 2002;17:207-15.
21. Schooler NR. Maintaining symptom control: Review of ziprasidone long-term efficacy data. J Clin Psychiatry 2003;64 (Suppl 19):26-32.
22. Caley CF, Cooper CK. Ziprasidone: The fifth atypical antipsychotic. Ann Pharmacother 2002;36:839-51.
23. Guy W. ECDEU assessment manual for psychopharmacology - revised (DHEW Publ. No ADM 76-338). Rockville, MD: U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs 1976: 218-22.
24. Global Assessment of Functioning Scale. In: American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition. Washington, DC: American Psychiatric Association; 1994:32.
25. Moss AJ. Long QT syndrome. JAMA 2003;289:2041-4.
26. Bednar MM, Harrigan EP, Anziano RJ, et al. The QT interval. Prog Cardiovasc Dis 2001;43(Suppl 1):1-45.
27. Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation: Implications for drug approval and labeling. Drug Safety 2001;24:323-51.
28. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60:553-64.
29. Leucht S, Barnes TR, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: Systematic review and exploratory meta analysis of randomized, controlled trials. Am J Psychiatry 2003;160:1209-22.